BK vs SPRO · P/E 17, rev $20.08B vs P/E 9.6, rev $48.0M
The Bank of New York Mellon Corporation (BK) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Latest reported BK revenue for 2025-12-31 was $20.08B. Net income was $5.55B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. BK currently screens at market cap $94.14B and trailing P/E 17.0.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
BK currently screens at market cap $94.14B and trailing P/E 17.0. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the BK and SPRO stock pages for the full models.
Not investment advice.